Benzoylecgonine (BZE) (BZE)

Benzoylecgonine is the primary metabolite of cocaine, formed in the liver through hydrolysis by carboxylesterases (Wikipedia, 2024; PubChem, 2024). It is significantly more stable than its parent compound, with a half-life of approximately 6 to 12 hours, making it the gold-standard biomarker for detecting cocaine use in urinalysis and forensic toxicology (NIH, 2024; Wikipedia, 2024). While it lacks the psychoactive effects of cocaine, it is biologically active and acts as a potent vasoconstrictor, particularly in cerebral arteries (PubMed, 2015; NIH, 2016). This activity is thought to contribute to the delayed or persistent cardiovascular and neurological toxicities observed in cocaine users (NIH, 2016). Benzoylecgonine is not a therapeutic target for drug development; rather, it is a metabolic byproduct and a focus of detoxification research, where engineered enzymes like butyrylcholinesterase are being developed to accelerate its clearance (NIH, 2016; ResearchGate, 2021).

Other names

Ecgonine benzoateCocaine metabolite3-(Benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylic acid(-)-Benzoylecgonine

Benzoylecgonine is a metabolite rather than a therapeutic target. It exerts biological effects, such as vasoconstriction, primarily by promoting the influx of extracellular calcium into smooth muscle cells, a mechanism distinct from the adrenergic activity of its parent compound, cocaine (PubMed, 1992; NIH, 2021).